Safety Trial of Single Versus Multiple Dose Thymoglobulin Induction in Kidney Transplantation (STAT)

Wright State University

Status and phase: Completed; Phase 2

Conditions: Kidney Failure; End-Stage Renal Disease

Treatments: Biological: Divided-dose rabbit Anti-thymocyte Globulin induction; Biological: Single-dose rabbit Anti-thymocyte Globulin induction

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00906204

183-09-FB

Details and patient eligibility

About

In a non-blinded pilot study conducted at the University of Nebraska Medical Center, evidence was found that a single large dose of Thymoglobulin on the day of kidney transplantation produced better kidney function than the standard dosing plan, when the same amount is divided into smaller doses on 4 days. This new study repeats that dose comparison, but with double-blinding and at multiple transplantation centers.

Full description

This study is designed to confirm the one-year safety of single-dose rabbit anti-thymocyte globulin induction at kidney transplantation, compared to the conventional administration of the same overall dose divided into four smaller doses across four days. Two randomized groups of kidney transplant recipients will be each administered the drug Thymoglobulin according to a different dosing regimen. The control group will receive the usual and traditional regimen of a total of 6 mg/Kg divided into 4 doses, 1 on the day of transplantation and 1 each day on the next 3 days. The experimental group will receive the same total Thymoglobulin dose, 6 mg/Kg, but entirely on the day of transplantation.

The study will be double-blinded, with placebo doses of Thymoglobulin administered as needed to enrollees in the experimental group. Enrollment is targeted at 165, with 150 subjects needed to complete the study for adequate evaluation.

Enrollment: 99 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subject capable of giving written informed consent, with end-stage kidney disease, who is a suitable candidate for primary kidney transplantation
• Male or female subject who has reached legal age in the state where they reside and is at least 18 years of age
• Deceased or living donors
• Compatible ABO blood type
• Expanded-criteria donor (ECD) kidneys with a donor grade score of ≤ 25 (as developed by Nyberg, et al.)
• If Kidneys are pumped, they must meet the following pumping parameters: resistance <0.35 with a flow rate of >60 ml/min.

Exclusion criteria

• Recipient age >65 years
• PRA >50%, or donor-specific antibody
• CIT >30 hours
• Re-transplant patients
• Multi-organ transplant recipients (example: kidney/pancreas or kidney/liver)
• Renal transplant recipients planned for future pancreas transplantation
• Current unstable cardiovascular disease or history of myocardial infarction within the previous 6 months
• Current malignancy or history or malignancy (within the previous 5 years) with the exception of non-metastatic basal or squamous cell carcinoma of the skin or carcinoma in-situ of the cervix that has been treated successfully.
• Hepatitis B and C recipients or active liver disease
• HIV positive recipients
• Primary disease requiring treatment with steroids after transplantation
• Expanded-criteria donor kidneys (current UNOS criteria) with a donor grade score of > 25
• Donation after cardiac death (DCD) donors
• Dual adult kidneys
• Recipients of pediatric (age <12 years) unilateral or en-bloc kidneys
• Previous treatment with rATG
• Known hypersensitivity, extensive exposure, or allergy to rabbits
• Pregnant
• Any condition that in the investigator's opinion may compromise study participation (e.g., history or likelihood of non-compliance with immunosuppression regimen, protocol visits, tests, and studies)

Relative Exclusion Criteria:

• Patients with a BMI > 37 should be considered on an individual basis based on overall health and body habitus.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

99 participants in 2 patient groups

Single-dose Thymoglobulin

Experimental group

Description:

Biological/Vaccine Single-dose rabbit Anti-thymocyte Globulin induction, 6 mg/kg IV infusion

Treatment:

Biological: Single-dose rabbit Anti-thymocyte Globulin induction

Divided-dose Thymoglobulin

Active Comparator group

Description:

Biological/Vaccine Divided-dose rabbit Anti-thymocyte Globulin induction, 1.5 mg/kg IV infusion QD x 4

Treatment:

Biological: Divided-dose rabbit Anti-thymocyte Globulin induction